announcement today about FDA clearance for use in diabetic ulcers ect.
thinking to myself
aroa still a biological product and Novosorb synthetic.
but why hasnt PNV commented or made any specific moves to market Novosorb in this space.
Aroa value the TAM for it as 1b+ in US alone.
does anyone know of any case studies or comments from management Around use to novosorb in chronic wounds with healing compromised by disease (diabetes)
cheers
announcement today about FDA clearance for use in diabetic...
-
- There are more pages in this discussion • 43 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PNV (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$2.42 |
Change
0.150(6.61%) |
Mkt cap ! $1.670B | |||
| Open | High | Low | Value | Volume |
| $2.33 | $2.42 | $2.29 | $4.630M | 1.958M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 3536 | $2.41 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $2.43 | 38315 | 8 |
View Market Depth
| Last trade - 16.10pm 26/06/2024 (20 minute delay) ? |
| PNV (ASX) Chart |